Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Fulcrum Therapeutics Inc. (FULC)

15.2   0.24 (1.6%) 02-14 16:00
Open: 14.9 Pre. Close: 14.96
High: 15.695 Low: 14.85
Volume: 24,894 Market Cap: 355M
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. The company has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 15.712 - 15.8 15.8 - 15.881
Low: 14.624 - 14.736 14.736 - 14.839
Close: 15.036 - 15.2 15.2 - 15.35

Technical analysis

as of: 2020-02-14 4:28:59 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 23.05     One year: 26.82
Support: Support1: 14.52    Support2: 12.08
Resistance: Resistance1: 19.74    Resistance2: 22.96
Pivot: 16.85
Moving Average: MA(5): 15.65     MA(20): 17.15
MA(100): 11.89     MA(250):
MACD: MACD(12,26): -0.27     Signal(9): 0.13
Stochastic oscillator: %K(14,3): 9.57     %D(3): 7.28
RSI: RSI(14): 41.75
52-week: High: 22.96  Low: 4.37  Change(%): 12.6
Average Vol(K): 3-Month: 6659  10-Days: 5788

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
FULC has closed above bottom band by 8.6%. Bollinger Bands are 21.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fulcrum Therapeutics (FULC) Up 65% In A Month, IPO Lockup Expires On Jan.14
Shares of Fulcrum Therapeutics Inc. (FULC) have gained 65 percent over the last one month as the Company progresses with its lead drug candidate Losmapimod in facioscapulohumeral dystrophy.

Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease
Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NasdaqGM
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 23.34
Shares Float (M) 9.30
% Held by Insiders 8.74
% Held by Institutions 65.21
Shares Short (K) 217
Shares Short P. Month (K)

Stock Financials

EPS -14.920
Book Value (p.s.) 4.530
PEG Ratio -0.69
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -3.211
Qtrly Earnings Growth
Operating Cash Flow (M) -41.39
Levered Free Cash Flow (M)

Stock Valuations

P/E -1.02
P/E Growth Ratio 0.02
P/BV 3.36
P/CF -8.57

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.